Incidence of Hand-Foot Syndrome in Metastatic Breast Cancer Patients Treated with Capecitabine in Middle Euphrates Region of Iraq
Main Article Content
Abstract
Background: Capecitabine is a fluoropyrimidine which is converted to 5-fluorouracil (5-FU) at the tumor site. Objectives: To evaluate the incidence of hand-foot syndrome (HFS) in metastatic breast cancer patients treated with capecitabine in our region. Methods: A retrospective descriptive study conducted at Al- Hussein cancer center in Karbala province of Iraq between April 2018 and August 2020.There were 58 female patients with metastatic breast cancer treated with capecitabine as monotherapy included in our study. Results: About 77.59% of our patients developed HFS , patients > 40 years old were the most affected age group in 84.44%. Majority of our patients were grade 1 in 66.67% and more than half patients (51.11%) developed their first episode of HFS after third cycle. Conclusion: Capecitabine is a well-tolerated treatment with low toxicity, most of our patients presented in early grades and first symptoms tend to occur after third cycle.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Lipworth A.D., Robert C. and Zhu A.X. "Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib". Oncology. 2009; 77(5):257-71.
Baack B.R. and Burgdorf W.H. "Chemotherapy-induced acral erythema". J Am Acad. Dermatol. 1991;24(3): 457-61. DOI: https://doi.org/10.1016/0190-9622(91)70073-B.
Miller K.K., Gorcey L. and McLellan B.N. "Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management". J Am Acad Dermatol. 2014; 71(4): 787-94. DOI: 10.1016/j.jaad.2014.03.019.
Bajetta E., Procopio G., Celio L., et al. "Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women". J Clin Oncol. 2005; 23(10): 2155-61. DOI: 10.1200/JCO.2005.02.167. 5. Gressett S.M., Stanford B.L. and Hardwicke F. " Management of hand-foot syndrome induced by Capecitabine". J Oncol Pharm Pract. 2006;12(3):131-41. DOI: https://doi.org/10.1177/1078155206069242.
Saif M.W. "Capecitabine and hand–foot syndrome". Expert Opin Drug Saf. 2011;10(2):159-69. DOI: 10.1517/14740338.2011.546342.
Abushullaih S., Saad E.D., Munsell M., et al. "Incidence and severity of hand–foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience". Cancer Invest. 2002; 20(1): 3-10. DOI: 10.1081/cnv-120000360.
Krishnegowda S.Y. and Kumar S.N. "Capecitabine-induced hand-foot syndrome". Egypt J Dermatol Venerol. 2014; 34(2):140. DOI: 10.4103/1110-6530.150277
Mjali A., Al-Shammari H.H., Abbas N.T., et al. "Leukemia Epidemiology in Karbala province of Iraq". Asian Pac J Cancer Care. 2019; 4(4):135-9.DOI: 10.31557/APJCC.2019.4.4.135-139.
Mjali A., Jawad S.A. and Al Baroodi B.N. "Gynecological Cancer in Middle Euphrates Region of Iraq, 2012-2020". Asian Pac Environ Cancer. 2020; 3(1):17-8. DOI 10.31557/APJEC.2020.3.1.17-18.
Hoesly F.J., Baker S.G., Gunawardane N.D., et al. "Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature". Arch Dermatol. 2011; 147(12):1418-23. DOI: 10.1001/archdermatol.2011.320.
Bray F., Ferlay J., Soerjomataram I., et al. "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA Cancer J Clin. 2018; 68(6): 394-424. DOI: 10.3322/caac.21492.
Mjali A. and Al Baroodi B.N. "Some Facts About Cancers in Karbala province of Iraq, 2012-2020". Asian Pac J Cancer Care. 2020; 5(2): 67-9. DOI 10.31557/APJCC.2020.5.2.67-69.
Mjali A., Sheikha A., Amin H.A., et al. "Association between Female Breast Cancer and Different ABO Blood Groups & Rh Factor in the Sulaymaniyah Province of Iraqi Kurdistan". Indian J Public Health Res Dev. 2019; 10(6): 454-9. DOI: https://doi.org/10.37506/ijphrd.v10i6.8160.
Mjali A., Al Baroodi B.N., Al–Shammari H.H., et al. "Skin Reaction at Site of Intrathecal Methotrexate". World J Pharm Res. 2019; 8 (10): 170-173. DOI: 10.20959/wjpr201910-15723.
Mjali A., Al-Anssari M.J. and Al-Shammari H.H. "Vincristine Induced Vocal Cord Paralysis in Patient with Diffuse Large B-cell Lymphoma: A Case Report". World J Pharm Res. 2017; 6(12): 11-15. DOI: 10.1186/1756-0500-7-318.
Azuma Y., Hata K., Sai K., et al. "Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer". Biol Pharm Bull. 2012; 35(5):717-24. DOI: 10.1248/bpb.35.717.
Sci. J. Med. Res. Vol. 4, Issue 16, pp 138- 141 Autumn 2020 140
.
Son H.S., Lee W.Y., Lee W.S., et al. "Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving Capecitabine as adjuvant chemotherapy". Yonsei Med J. 2009; 50(6): 796-802. DOI: 10.3349/ymj.2009.50.6.796.
Müller V., Fuxius S., Steffens C.C., et al. "Quality of life under Capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a German non-interventional surveillance study". Oncol Res Treat. 2014; 37(12):748-55.
Alwan N.A., Tawfeeq F.N. and Mallah N.A. "Demographic and clinical profiles of female patients diagnosed with breast cancer in Iraq". J Contemp. Med Sci. 2019; 5(1):14-9.
Palaniappan M., Srinivasamurthy S., Dubashi B., et al. "Anticancer drug induced palmar plantar erythrodysesthesia". J
Clin Diagn Res. 2014; 8(10): HC01. DOI: 10.7860/JCDR/2014/9133.4975.
Matsuoka H., Katagata Y., Ohta H., et al. "Multidisciplinary approach to the management of capecitabine-associated hand foot syndrome in cancer patients receiving capecitabine plus oxaliplatin and bevacizumab for advanced colorectal cancer". Fujita medical J. 2017; 3(1):1-5. DOI: https://doi.org/10.20407/fmj.3.1_1.
Yap Y.S., Kwok L.L., Syn N., et al. "Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine–Induced Hand-Foot Syndrome: A Randomized Clinical Trial". JAMA oncol. 2017; 3(11): 1538-45. DOI: 10.1001/jamaoncol.2017.1269.